149 related articles for article (PubMed ID: 37868433)
1. Effects of Teriparatide Treatment on Bone Mineral Density in Patients With Osteoporosis: A Short-Term Dose-Response Study.
Roy AN; Mazumdar I
Cureus; 2023 Sep; 15(9):e45662. PubMed ID: 37868433
[TBL] [Abstract][Full Text] [Related]
2. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
[TBL] [Abstract][Full Text] [Related]
3. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different parameters between daily and twice-weekly teriparatide in postmenopausal women with severe osteoporosis.
Mochizuki T; Yano K; Ikari K; Okazaki K
J Bone Miner Metab; 2023 Mar; 41(2):220-226. PubMed ID: 36625920
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis GN; Efstathiadou Z; Kita M; Avramidis A
Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
[TBL] [Abstract][Full Text] [Related]
6. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
[TBL] [Abstract][Full Text] [Related]
7. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling.
Winzenrieth R; Ominsky MS; Wang Y; Humbert L; Weiss RJ
Osteoporos Int; 2021 Mar; 32(3):575-583. PubMed ID: 33496831
[TBL] [Abstract][Full Text] [Related]
9. Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis.
Lee S; Hong N; Kim KJ; Park CH; Lee J; Rhee Y
Calcif Tissue Int; 2021 Nov; 109(5):544-553. PubMed ID: 34037833
[TBL] [Abstract][Full Text] [Related]
10. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis.
Hong N; Kim JE; Lee SJ; Kim SH; Rhee Y
Clin Endocrinol (Oxf); 2018 May; 88(5):652-658. PubMed ID: 29389010
[TBL] [Abstract][Full Text] [Related]
11. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
[TBL] [Abstract][Full Text] [Related]
12. Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs.
Song J; Jin Z; Chang F; Li L; Su Y
Med Sci Monit; 2014 Dec; 20():2624-32. PubMed ID: 25503108
[TBL] [Abstract][Full Text] [Related]
13. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
Cosman F; Nieves JW; Dempster DW
J Bone Miner Res; 2017 Feb; 32(2):198-202. PubMed ID: 27925287
[TBL] [Abstract][Full Text] [Related]
14. DEXA sensitivity analysis in patients with adult spinal deformity.
Gupta A; Upadhyaya S; Patel A; Fogel HA; Cha T; Schwab J; Bono C; Hershman S
Spine J; 2020 Feb; 20(2):174-180. PubMed ID: 31479779
[TBL] [Abstract][Full Text] [Related]
15. The anabolic effect of teriparatide is undermined by low levels of high-density lipoprotein cholesterol.
Jeon YK; Kim KM; Kim KJ; Kim IJ; Lim SK; Rhee Y
Calcif Tissue Int; 2014 Feb; 94(2):159-68. PubMed ID: 23907724
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate Pre-Treatment Diminishes the Therapeutic Benefits of Teriparatide in Japanese Osteoporotic Patients.
Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H
Tohoku J Exp Med; 2016 May; 239(1):17-24. PubMed ID: 27150954
[TBL] [Abstract][Full Text] [Related]
17. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
18. Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.
Takeuchi Y; Kuroda T; Sugimoto T; Shiraki M; Nakamura T
Calcif Tissue Int; 2016 Feb; 98(2):186-92. PubMed ID: 26478225
[TBL] [Abstract][Full Text] [Related]
19. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
[TBL] [Abstract][Full Text] [Related]
20. Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis.
Mastaglia SR
J Clin Densitom; 2017; 20(4):513-515. PubMed ID: 28579148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
